When the FDA calls an official controversial, it rarely means the science broke; it means the pecking order did. Prasad’s exit is the latest round of that fight.
Dissent became distraction by design
wbur.org reported March 10, 2026, that Vinay Prasad will leave the FDA after decisions on vaccines and gene therapies sparked internal and external tension. His first resignation in July 2025 came with a statement that he did not want to become a distraction, per AP and STAT coverage at the time; he was back within weeks at the agency’s request. That pattern matters: the agency could not afford the optics of open war with its CBER chief, yet it also could not absorb his pace of public conflict with sponsors.
Consensus here means who controls the narrative
NPR and WBUR pieces framed the Moderna flu episode as unprecedented: refusal to accept an application sponsors believed had been pre-cleared through meetings, then a reversal. STAT reported staff fear and turnover inside CBER during 2025. Those are not disputes over whether mRNA works; they are disputes over who gets to redraw the evidentiary bar after companies spend nine figures on trials.
What This Actually Means
Labeling Prasad controversial let the institution avoid debating whether his evidentiary demands were right. His departure closes the chapter without resolving the underlying question: who inside FDA can still say no when HHS and sponsors align on speed.